LivaNova PLC (NASDAQ:LIVN) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 286.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 207,248 shares of the company's stock after purchasing an additional 153,611 shares during the period. The Manufacturers Life Insurance Company owned about 0.38% of LivaNova worth $10,889,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LIVN. Driehaus Capital Management LLC raised its position in shares of LivaNova by 64.7% during the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after purchasing an additional 213,749 shares during the period. Perceptive Advisors LLC boosted its position in shares of LivaNova by 48.5% during the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after buying an additional 145,000 shares during the period. Great Lakes Advisors LLC purchased a new position in LivaNova in the 2nd quarter worth about $16,614,000. Price T Rowe Associates Inc. MD raised its position in LivaNova by 6.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company's stock valued at $1,736,000 after purchasing an additional 1,980 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of LivaNova during the second quarter valued at approximately $1,103,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on LIVN shares. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 17th. The Goldman Sachs Group assumed coverage on LivaNova in a research report on Friday, October 4th. They issued a "buy" rating and a $65.00 target price on the stock. Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Finally, Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus price target of $69.17.

LivaNova Stock Performance

NASDAQ:LIVN traded down $0.98 during midday trading on Tuesday, reaching $51.31. The stock had a trading volume of 87,703 shares, compared to its average volume of 607,820. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.79 billion, a P/E ratio of 122.17 and a beta of 0.98. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a fifty day simple moving average of $52.29 and a two-hundred day simple moving average of $52.03.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.